Xiao Lin, Yu Xin, Zhang Rong, Chang Hui, Xi Shaoyan, Xiao Weiwei, Zeng Zhifan, Zhang Huizhong, Xu Ruihua, Gao Yuanhong
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
Oncotarget. 2016 Jun 7;7(23):34149-57. doi: 10.18632/oncotarget.9178.
We sought to determine whether a polymorphism in the Interleukin 13 gene (IL13), 1112 C/T (rs1800925) predicts responsiveness to neoadjuvant chemoradiotherapy (neoCRT) and prognosis in Chinese Han patients with locally advanced rectal cancer (LARC). Pre-treatment biopsies of primary rectal lesion and surgical specimens were collected from 58 patients with LARC, who were treated with neoCRT and surgery. Tumor DNA was extracted from these biopsies and sequenced to analyze the rs1800925 polymorphism. The tumor response to neoCRT was categorized using a tumor regression grade (TRG, 0-2 were poor responders; 3-4 were good responders). Analyses of progression free survival (PFS) and overall survival (OS) were carried out using the Kaplan-Meier method. Of the forty-six patients for whom tumor DNA was successfully sequenced, 23 were good responders to neoCRT (11 patients with a pathological complete response, i.e. pCR) and the other 23 were poor responders. Good and poor responders were equally likely to have a C/C genotype at rs1800925 (73.9%) as a T/T or C/T genotype (26.1%). There were no differences between the C/C and T/T+C/T genotypes with respect to the ypT0-2 ratio (38.2% vs. 41.7%, P = 1.0) , ypN0 nodal status (67.6% vs. 50.0%, P= 0.314), 6-year PFS (67.6% vs. 50%, P=0.274), or 6-year OS (76.5% vs. 66.7%, P=0.441). Thus, the IL13-1112 C/T (rs1800925) polymorphism does not predict responsiveness to neoCRT or prognosis of Chinese Han patients with LARC.
我们试图确定白细胞介素13基因（IL13）中的1112 C/T（rs1800925）多态性是否能预测中国汉族局部晚期直肠癌（LARC）患者对新辅助放化疗（neoCRT）的反应性及预后。收集了58例接受neoCRT和手术治疗的LARC患者的原发性直肠病变治疗前活检组织及手术标本。从这些活检组织中提取肿瘤DNA并进行测序，以分析rs1800925多态性。使用肿瘤退缩分级（TRG，0 - 2级为反应不佳者；3 - 4级为反应良好者）对neoCRT的肿瘤反应进行分类。采用Kaplan-Meier法进行无进展生存期（PFS）和总生存期（OS）分析。在成功进行肿瘤DNA测序的46例患者中，23例对neoCRT反应良好（11例达到病理完全缓解，即pCR），另外23例反应不佳。反应良好者和反应不佳者在rs1800925处具有C/C基因型（73.9%）与T/T或C/T基因型（26.1%）的可能性相同。C/C与T/T + C/T基因型在ypT0 - 2比例（38.2%对41.7%，P = 1.0）、ypN0淋巴结状态（67.6%对50.0%，P = 0.314）、6年PFS（67.6%对50%，P = 0.274）或6年OS（76.5%对66.7%，P = 0.441）方面均无差异。因此，IL13 - 1112 C/T（rs1800925）多态性不能预测中国汉族LARC患者对neoCRT的反应性或预后。
